Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 16/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
| ▸ | DRD4 | P21917 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | DRD3 | P35462 | 1/20 | 0.49 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6776764 | 0.86 | HTR1A (0.51) | HTR1ACYP3A4DRD2DRD4DRD3 | |
| SCHEMBL6007524 | 0.86 | HTR1A (0.68) | HTR1A | |
| SCHEMBL5912614 | 0.84 | HTR1A (0.63) | HTR1ACYP3A4CYP2C8DRD2DRD4 | |
| SCHEMBL6906269 | 0.77 | HTR1A (0.61) | HTR1ACYP3A4CYP2C8DRD2DRD4 | |
| SCHEMBL6907539 | 0.76 | HTR1A (0.69) | HTR1ACYP3A4CYP2C8DRD2DRD4 | |
| SCHEMBL4187208 | 0.75 | HTR1A (0.65) | HTR1ACYP3A4CYP2C8DRD2DRD4 | |
| SCHEMBL5912602 | 0.74 | HTR1A (0.66) | HTR1ACYP3A4CYP2C8DRD2DRD4 | |
| SCHEMBL5912597 | 0.74 | HTR1A (0.66) | HTR1ACYP3A4CYP2C8DRD2DRD4 | |
| SCHEMBL5912692 | 0.74 | HTR1A (0.73) | HTR1ACYP3A4CYP2C8DRD2DRD4 | |
| SCHEMBL5112827 | 0.74 | HTR1A (0.69) | HTR1AOPRL1OPRM1OPRK1SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6821981-B2 | FOR THERAPY OF DISORDERS, SUCH AS ANXIETY, AGGRESSION AND STRESS, AND FOR THE CONTROL OF VARIOUS PHYSIOLOGICAL PHENOMENA, SUCH AS APPETITE, THERMOREGULATION, SLEEP AND SEXUAL BEHAVIOR | WYETH | 2004-11-23 | — | — | US | claimed |
| US-20020193366-A1 | Azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-dioxino[2,3-f]-quinoline as 5-HT1A antagonists | WYETH | 2002-12-19 | — | — | US | claimed |
| WO-2002088132-A1 | AZAHETEROCYCLYLMETHYL DERIVATIVES OF 2,3-DIHYDRO-1,4-DIOXINO[2,3-F]QUINOLINE AS 5-HT1AANTAGONISTS | WYETH (US) | 2002-11-07 | — | — | WO | claimed |
| US-6821981-B2 | FOR THERAPY OF DISORDERS, SUCH AS ANXIETY, AGGRESSION AND STRESS, AND FOR THE CONTROL OF VARIOUS PHYSIOLOGICAL PHENOMENA, SUCH AS APPETITE, THERMOREGULATION, SLEEP AND SEXUAL BEHAVIOR | WYETH | 2004-11-23 | — | — | US | disclosed |
| US-20020193366-A1 | Azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-dioxino[2,3-f]-quinoline as 5-HT1A antagonists | WYETH | 2002-12-19 | — | — | US | disclosed |
| WO-2002088132-A1 | AZAHETEROCYCLYLMETHYL DERIVATIVES OF 2,3-DIHYDRO-1,4-DIOXINO[2,3-F]QUINOLINE AS 5-HT1AANTAGONISTS | WYETH (US) | 2002-11-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193366-A1 | Azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-dioxino[2,3-f]-quinoline as 5-HT1A antagonists | HTR2C, HTR1A, HTR3B | HTR1A 2/4885CYP3A4 259/4885CYP2C8 809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.